Zobrazeno 1 - 10
of 89
pro vyhledávání: '"A. R. Kugler"'
Autor:
Mosun Ayan-Oshodi, Douglas E. James, Jennifer A. Zimmer, Brian A. Willis, Scott A. Monk, Scott W. Andersen, Alan R. Kugler, Jamie Mullen
Publikováno v:
The Journal of Clinical Pharmacology. 60:586-594
Lanabecestat, a novel β-site amyloid precursor protein-cleaving enzyme 1 inhibitor evaluated for Alzheimer treatment, inhibits P-glycoprotein (P-gp) activity in vitro. After oral 50-mg lanabecestat administration, gastric fluid lanabecestat concentr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c781a369f1140b257f43abcecb817d64
https://doi.org/10.1002/jcph.1558
https://doi.org/10.1002/jcph.1558
Publikováno v:
CNS Drugs
Background Given the limited treatment options for younger children with attention-deficit/hyperactivity disorder (ADHD), a clinical study for SHP465 treatment was warranted. Objectives We aimed to evaluate the pharmacokinetics, safety, and tolerabil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16af88fb928f0af3496d04517a05a575
https://pubmed.ncbi.nlm.nih.gov/34826114
https://pubmed.ncbi.nlm.nih.gov/34826114
Publikováno v:
Epilepsy research. 174
Background In Japan, intravenous (IV) administration of antiepileptic drugs in a healthcare setting is the preferred treatment option that is both licensed and recommended for initial treatment of status epilepticus (SE). However, prompt conveyance t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d8907a2dcbace555a1ec76194e43514
https://pubmed.ncbi.nlm.nih.gov/34020149
https://pubmed.ncbi.nlm.nih.gov/34020149
Autor:
Kyoko Matsuguma, Susanna Eketjäll, Tatsuya Yoshihara, Fumihiko Azuma, Glen Hughes, Kei Sakamoto, Alan R. Kugler, Robert C. Alexander, Naoki Uchida, Muir Russell, Samantha Budd Haeberlein, Shunji Matsuki
Publikováno v:
The Journal of Clinical Pharmacology. 57:1460-1471
Lanabecestat (AZD3293; LY3314814) is an orally active potent inhibitor of human β-secretase 1 in clinical development for the treatment of Alzheimer disease. In this first Japanese clinical study for an Alzheimer disease intervention to include cere
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7b8ab5558f619a1893ded62f15383ce
https://doi.org/10.1002/jcph.950
https://doi.org/10.1002/jcph.950
Publikováno v:
Bioanalysis. 9:813-826
Aim: AZD3293 is a novel BACE1 inhibitor in Phase III development for Alzheimer's disease. Sensitive and robust bioanalytical methods were required to quantitate AZD3293 and its metabolite AZ13569724 in human biological matrices. Methodology/results:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c90b674146000f7c9b513415ba980d15
https://doi.org/10.4155/bio-2017-0003
https://doi.org/10.4155/bio-2017-0003
Autor:
Karin Kaspersson, Juliette Janson, Johanna Fälting, Gvido Cebers, Samantha Budd Haeberlein, Fredrik Jeppsson, Susanna Eketjäll, Alan R. Kugler, Anna Bogstedt, Robert C. Alexander
Publikováno v:
Journal of Alzheimer's Disease
A growing body of pathological, biomarker, genetic, and mechanistic data suggests that amyloid accumulation, as a result of changes in production, processing, and/or clearance of brain amyloid-β peptide (Aβ) concentrations, plays a key role in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65beb77a630968cc8f1f9d69367c2ef9
https://doi.org/10.3233/jad-150834
https://doi.org/10.3233/jad-150834
Publikováno v:
Journal of the American Academy of Child & Adolescent Psychiatry. 59:S155
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6547df067902fb6d8d1756ae9860e9a9
https://doi.org/10.1016/j.jaac.2020.08.081
https://doi.org/10.1016/j.jaac.2020.08.081
Autor:
E W Ingersoll, S Platz, T Lejeune, Gvido Cebers, Clay W Scott, Alan R. Kugler, Robert C. Alexander, B Attalla, S Budd Haeberlein, M Soderberg
Publikováno v:
The journal of prevention of Alzheimer's disease. 3(4)
Background: AZD3293 (also known as LY3314814) is a novel, potent, non-selective BACE1/BACE2 inhibitor currently in Phase 3 clinical development for the treatment of Alzheimer’s disease. Objectives: The purpose of these studies was to characterize t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b43302f9ef80366d010404e347a6c23
https://pubmed.ncbi.nlm.nih.gov/29199322
https://pubmed.ncbi.nlm.nih.gov/29199322
Autor:
Andrea Varrone, Per Svenningsson, Katarina Varnäs, Peter Johnström, Anna K. Kirjavainen, Margaret Minkwitz, Zsolt Cselényi, Juha O. Rinne, Nahid Amini, Joel A. Posener, Aurelija Jucaite, Semi Helin, Samantha L. Budd, Alan R. Kugler, Lars Farde, Christer Halldin
Publikováno v:
Brain. 138:2687-2700
Impaired mitochondrial function, oxidative stress and formation of excessive levels of reactive oxygen species play a key role in neurodegeneration in Parkinson’s disease. Myeloperoxidase is a reactive oxygen generating enzyme and is expressed by m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12a0536de57e1a2b3f3347b6dc3ccc89
https://doi.org/10.1093/brain/awv184
https://doi.org/10.1093/brain/awv184
Autor:
Kei, Sakamoto, Shunji, Matsuki, Kyoko, Matsuguma, Tatsuya, Yoshihara, Naoki, Uchida, Fumihiko, Azuma, Muir, Russell, Glen, Hughes, Samantha Budd, Haeberlein, Robert C, Alexander, Susanna, Eketjäll, Alan R, Kugler
Publikováno v:
Journal of clinical pharmacology. 57(11)
Lanabecestat (AZD3293; LY3314814) is an orally active potent inhibitor of human β-secretase 1 in clinical development for the treatment of Alzheimer disease. In this first Japanese clinical study for an Alzheimer disease intervention to include cere
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::87144b0fd598b9458837d9d210282b8d
https://pubmed.ncbi.nlm.nih.gov/28618005
https://pubmed.ncbi.nlm.nih.gov/28618005